LAS VEGAS, NV, United States, via ETELIGIS INC., 10/20/2014 – – RAMOIL MANAGEMENT, Ltd (OTC Pink: RAMO) (PINKSHEETS: RAMO), announced that its wholly owned subsidiary, RAMO Bio-Med, Inc., has created a proprietary high CBD, extremely low THC formula to aid a Southern California victim of West Nile Virus.
The female patient, who asks not to be identified, said, “I caught a severe case of West Nile virus, I’ve got paralysis and severe pain in my right leg. Since there is no anti viral medicine for this virus, the only thing doctors can do is pain management. The five prescription pain meds I had been taking to deal with the constant and chronic pain of West Nile Virus were not working. After just two weeks using the RAMO Bio-Med CBD Formula, I am down to only one prescription pain med, have my appetite back and have returned to work. I still have a long way to go to recover from the paralysis but my pain is manageable for the first time since contracting the disease, I am back to work and feel like I’m improving every day. Thank you RAMO Bio-Med, I’m grateful for your CBD formula!!”
Michael Goeree, Ramoil Management’s Chairman, President and Chief Executive Officer, said, “The patient is the sister of one of our largest shareholders. We are delighted the RAMO Bio-Med CBD Formula has benefited a member of the RAMO Family. We believe it will benefit others, as well.”
About Ramoil Management, Ltd.
Ramoil Management, Ltd. (RAMO) is a development stage company. The Company is an online wholesaler of E-cigarettes containing nutraceutical vapor oils, E-cigarette delivery systems and hydroponic lighting and nutrients. Through its wholly owned subsidiary, RAMO Bio-Med, Inc., it is operating a “Supercritical CO2 Molecular Extraction” system and is planning to build production facilities and research labs, both domestically and internationally, focused on its own proprietary strain of high CBD – extremely low THC Extraction Facilities (Labs and Manufacturing), for the development, production and sales of CBD extractions, concentrates and medicines.
Forward Looking Statements:
This news release contains forward-looking statements made by RAMOIL MANAGEMENT, LTD. All such statements included in this press release, other than statements of historical fact, are forward-looking statements. Although management believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. Actual results may differ materially from those indicated by these statements. The following risk factors, among others, could cause actual results to differ materially from those described in any forward-looking statements. These risks and uncertainties include, but are not limited to, economic conditions, changes in the law or regulations, demand for products of the Company, the effects of competition and other factors that could cause actual results to differ materially from those projected or represented in the forward looking statements. Forward-looking statements are typically identified by the words: believe, expect, anticipate, intend, estimate, and similar expressions or which by their nature refer to future events. The Company is not entitled to rely on the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 because it is not registered under either Act.
Company and Investor Relations Contact:
Frank Blainey, Esq. at:
SOURCE Ramoil Management, Ltd.